SCHEMBL16093012

SCHEMBL16093012

Cc1ccc(/C=C/C(=O)/C=C/c2ccc(O)c(O)c2)cc1O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IAPP P10997 4/20 0.64
PTGS1 P23219 1/20 0.64
TTR P02766 3/20 0.61
MMP1 P03956 3/20 0.61
MMP2 P08253 3/20 0.61
MMP9 P14780 3/20 0.61
KDM4E B2RXH2 2/20 0.61
HSD17B10 Q99714 2/20 0.61
APP P05067 2/20 0.61
DPP4 P27487 2/20 0.61
ALOX5 P09917 2/20 0.61
NFKB1 P19838 2/20 0.61
MAPT P10636 2/20 0.61
PTPN1 P18031 2/20 0.61
MEN1 O00255 1/20 0.61
HDAC3 O15379 1/20 0.61
CA12 O43570 1/20 0.61
AKR1B10 O60218 1/20 0.61
ALDH1A1 P00352 1/20 0.61
CA1 P00915 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5598948 0.89 KDM4E (0.74) IAPPPTGS1TTRMMP1MMP2
SCHEMBL2221673 0.89 KDM4E (0.74) IAPPPTGS1TTRMMP1MMP2
SCHEMBL16881737 0.87 IAPP (0.69) IAPPPTGS1TTRMMP1MMP2
SCHEMBL8349121 0.84 SNCA (0.82) MAPTTERTSNCA
SCHEMBL15481424 0.84 BACE1 (0.66) IAPPPTGS1TTRMMP1MMP2
SCHEMBL21986720 0.82 IAPP (0.73) IAPPPTGS1TTRMMP1MMP2
SCHEMBL14472602 0.82 KDM4E (0.70) IAPPPTGS1TTRMMP1MMP2
SCHEMBL21986902 0.82 IAPP (0.73) IAPPPTGS1TTRMMP1MMP2
SCHEMBL10021657 0.82 CYP2C9 (0.74) IAPPPTGS1TTRMMP1MMP2
SCHEMBL13953735 0.82 BACE1 (0.57) IAPPPTGS1TTRMMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9925153-B2 Therapeutic agents for skin diseases and conditions STC.UNM (US) 2018-03-27 US disclosed
US-20160287531-A1 THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS STC.UNM 2016-10-06 US disclosed
US-8841326-B2 Therapeutic curcumin derivatives STC.UNM (US) 2014-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160287531-A1 THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS CUTA, TSLP, ELANE IAPP 1553/4885PTGS1 1081/4885TTR 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.